FDA label 5095a3f5-1528-4b55-b095-6d8e182ccfe8

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
dcf785b2-e923-43bf-93bb-00a9501479f4
SPL ID
5095a3f5-1528-4b55-b095-6d8e182ccfe8
Version
4
Effective date
2012-09-17
Source export date
2026-11-13
Source partition
13
Source file
https://download.open.fda.gov/drug/label/drug-label-0013-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/59f616a891fdb32b85469f3498f080490e31c92c33c42932fcf32980bd661882/drug-label-0013-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:59:07

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

Adverse Reactions: Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of dipyridamole tablets initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets and warfarin therapy to either warfarin alone or warfarin and placebo: Table 1: Adverse Reactions Reported in 2 Heart Valve Replacement Trials Adverse Reaction Dipyridamole Tablets/ Warfarin Placebo/ Warfarin Number of Patients 147 170 Dizziness 13.6% 8.2% Abdominal distress 6.1% 3.5% Headache 2.3% 0.0% Rash 2.3% 1.1% Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely, and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication. When dipyridamole tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased bleeding during or after surgery has been observed. In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis, hypotension, palpitation, and tachycardia.

adverse reactions table

<table><caption>Table 1: Adverse Reactions Reported in 2 Heart Valve Replacement Trials</caption><col/><col/><col/><tbody><tr><td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Adverse Reaction</content></td><td align="center" valign="top" styleCode=" Botrule Rrule "> <content styleCode="bold">Dipyridamole Tablets/ Warfarin</content></td><td align="center" valign="top" styleCode=" Botrule Rrule "> <paragraph><content styleCode="bold">Placebo/</content></paragraph><content styleCode="bold">Warfarin</content></td></tr><tr><td valign="top" styleCode=" Botrule Lrule Rrule "> Number of Patients</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 147</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 170</td></tr><tr><td valign="top" styleCode=" Botrule Lrule Rrule "> Dizziness</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 13.6%</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 8.2%</td></tr><tr><td valign="top" styleCode=" Botrule Lrule Rrule "> Abdominal distress</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 6.1%</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 3.5%</td></tr><tr><td valign="top" styleCode=" Botrule Lrule Rrule "> Headache</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 2.3%</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 0.0%</td></tr><tr><td valign="top" styleCode=" Botrule Lrule Rrule "> Rash</td><td align="center" valign="top" styleCode=" Rrule "> 2.3%</td><td align="center" valign="top" styleCode=" Botrule Rrule "> 1.1%</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.